Maisrh Alrubaye

Maisrh Alrubaye

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2026 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZLZainab Lafi
Zainab Lafi
MAMansour Al-Sayed Ahmad
Mansour Al-Sayed Ahmad
AKAya Y AL Kabariti
Aya Y AL Kabariti
MAMaisrh Alrubaye
Maisrh Alrubaye
WSWala’A Al. Safadi
Wala’A Al. Safadi
ZDZaid ABU Diak
Zaid ABU Diak
Despite the reported anticancer activities of phytocompounds such as curcumin, resveratrol, and quercetin, their clinical application remains limited. Therefore, since the invention of lipid-based nanoparticles (LBNPs), they were used to deliver low bioavailable bioactive compounds. Many types of lipid NPs emerged such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and phytosomes. Engineered LBNPs provide controlled drug release, enhance accumulation at tumor sites through passive or active targeting mechanisms. This review discusses recent advances in LBNP delivery for phytocompounds, with emphasis on preparation methods, physicochemical characterization, and application examples. This review focuses on limitations of clinical translation, including the absence of standardized formulation procedures, inconsistent reporting of critical quality attributes, insufficient long-term safety data, manufacturing challenges, and regulatory requirements. In conclusion, LBNP toxicity and biodistribution depend on formulation characteristics, dose, biological environment, and administration route, and that active targeting may improve selectivity but does not completely eliminate off-target distribution or exposure to healthy tissues.

18 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZLZainab Lafi
Zainab Lafi
MAMohammad IA Ahmad
Mohammad IA Ahmad
NNNusair Nusair
Nusair Nusair
RMRazan Hashem Madi
Razan Hashem Madi
ASAlaa Mohammad Sanabrh
Alaa Mohammad Sanabrh
SASara Yousef Asha
Sara Yousef Asha
Background: Diabetes-associated wound healing is frequently impaired due to persistent hyperglycemia, which causes vascular dysfunction and neuropathy, thereby delaying tissue repair. Objectives: In this study, hyaluronic acid and protamine nanoparticles (HA-PRO-NPs) were developed and optimized to encapsulate disulfiram (DSF) and coumarin (COM) for potential application in diabetic wound healing. Methods: The nanoparticles were prepared using a simple ionic interaction method and characterized for their particle size, zeta potential, morphology and encapsulation efficiency. Then, HA-PRO-NPs were incorporated into a hydrogel that contains carboxymethyl cellulose (CMC) and propylene glycol (PG). The hydrogel formulations were evaluated for swelling behavior, spreadability and DSF and COM release kinetics. Results: The prepared formulations were safe against human dermal fibroblasts (HDFs), with cell viability remaining above 70% over the concentration ranges tested. In the scratch assay, HA-PROT-DSF-COM-NPs improved HDF migration, achieving approximately 81% wound closure. An in vivo study was conducted using streptozotocin-induced diabetic mice. Topical application of Gel-HA-PROT-DSF-COM-NPs promoted wound closure. The study monitored wound contraction on Days 0, 3, 7, and 12. By Day 12, topical administration of the dual-cargo system (Gel-HA-PROT-DSF-COM NPs, n = 6) achieved 78.2 ± 4.1% wound closure. This was significantly higher than the single-drug formulation (Gel-HA-PROT-DSF-NPs: 59.5 ± 4.8%) and the untreated Control (Diabetic) group (55.4 ± 5.2%, p < 0.01), while the non-diabetic Control group (non diabetic) reached 97.6 ± 3.5% closure. Semi-quantitative histopathological evaluation showed that the Gel-HA-PROT-DSF-COM NPs achieved a healing score of 4/5, characterized by optimized epidermal regeneration with preserved adnexal structures and moderate dermal remodeling. Conclusions: In conclusion, Gel-HA-PROT-DSF-COM-NPs demonstrated promising potential as a topical formulation for improving wound healing under diabetic conditions.